353 related articles for article (PubMed ID: 12171484)
21. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
[TBL] [Abstract][Full Text] [Related]
22. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
[TBL] [Abstract][Full Text] [Related]
23. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation.
Deeg HJ; Amylon ID; Harris RE; Collins R; Beatty PG; Feig S; Ramsay N; Territo M; Khan SP; Pamphilon D; Leis JF; Burdach S; Anasetti C; Hackman R; Storer B; Mueller B
Biol Blood Marrow Transplant; 2001; 7(4):208-15. PubMed ID: 11349807
[TBL] [Abstract][Full Text] [Related]
24. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
[TBL] [Abstract][Full Text] [Related]
25. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
[TBL] [Abstract][Full Text] [Related]
26. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Carella AM; Lerma E; Dejana A; Corsetti MT; Celesti L; Bruni R; Benvenuto F; Figari O; Parodi C; Carlier P; Florio G; Lercari G; Valbonesi M; Casarino L; De Stefano F; Geniram A; Venturino M; Tedeschi L; Palmieri G; Piaggio G; Podestà M; Frassoni F; Van Lint MT; Marmont AM; Bacigalupo A
Haematologica; 1998 Oct; 83(10):904-9. PubMed ID: 9830799
[TBL] [Abstract][Full Text] [Related]
27. The use of counterflow centrifugal elutriation for the depletion of T cells from unrelated donor bone marrow.
Neudorf SM; Rybka W; Ball E; Blatt J; Bloom E; Corey S; deMagalhaes-Silverman M; Koehler M; Lister J; Mierski J; Mirro J; Pincus S; Wilson J; Wollman M; Donnenberg AD
J Hematother; 1997 Aug; 6(4):351-9. PubMed ID: 9377073
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning.
Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A
Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862
[TBL] [Abstract][Full Text] [Related]
29. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA.
Mackinnon S; Barnett L; Bourhis JH; Black P; Heller G; O'Reilly RJ
Blood; 1992 Dec; 80(12):3235-41. PubMed ID: 1467526
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants.
Gaziev D; Galimberti M; Lucarelli G; Polchi P; Giardini C; Angelucci E; Baronciani D; Sodani P; Erer B; Biagi MD; Andreani M; Agostinelli F; Donati M; Nesci S; Talevi N
Bone Marrow Transplant; 2000 Apr; 25(8):815-21. PubMed ID: 10808201
[TBL] [Abstract][Full Text] [Related]
32. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD.
Petrus MJ; Williams JF; Eckhaus MA; Gress RE; Fowler DH
Biol Blood Marrow Transplant; 2000; 6(2A):182-9. PubMed ID: 10816026
[TBL] [Abstract][Full Text] [Related]
33. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
Georges GE; Maris M; Sandmaier BM; Malone DG; Feinstein L; Niederweiser D; Shizuru JA; McSweeney PA; Chauncey TR; Agura E; Little MT; Sahebi F; Hegenbart U; Pulsipher MA; Bruno B; Forman S; Woolfrey AE; Radich JP; Blume KG; Storb R
Int J Hematol; 2002 Aug; 76 Suppl 1():184-9. PubMed ID: 12430851
[TBL] [Abstract][Full Text] [Related]
34. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
36. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.
Luznik L; Bolaños-Meade J; Zahurak M; Chen AR; Smith BD; Brodsky R; Huff CA; Borrello I; Matsui W; Powell JD; Kasamon Y; Goodman SN; Hess A; Levitsky HI; Ambinder RF; Jones RJ; Fuchs EJ
Blood; 2010 Apr; 115(16):3224-30. PubMed ID: 20124511
[TBL] [Abstract][Full Text] [Related]
37. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
38. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.
Andersson BS; Kashyap A; Gian V; Wingard JR; Fernandez H; Cagnoni PJ; Jones RB; Tarantolo S; Hu WW; Blume KG; Forman SJ; Champlin RE
Biol Blood Marrow Transplant; 2002; 8(3):145-54. PubMed ID: 11939604
[TBL] [Abstract][Full Text] [Related]
39. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.
Barker JN; Weisdorf DJ; DeFor TE; Blazar BR; Miller JS; Wagner JE
Blood; 2003 Sep; 102(5):1915-9. PubMed ID: 12738676
[TBL] [Abstract][Full Text] [Related]
40. Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning.
Prigozhina TB; Elkin G; Khitrin S; Slavin S
Exp Hematol; 2004 Nov; 32(11):1110-7. PubMed ID: 15539090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
